STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Karo Bio announces today that data from a clinical proof of concept phase IIb study with eprotirome has been accepted for presentation at the Late-Breaking-Clinical-Trial session at the Annual American College of Cardiology Meeting in Orlando, Florida, March 29-31. The presentation will be given by Professor Bo Angelin from the Karolinska University Hospital, Stockholm on March 29 with the title “Eprotirome as a Novel and Physiological Approach to CVD Risk Reduction: Beneficial Effects on Lipoprotein Levels When Added to Statin Therapy”.
